Changes to Sobi’s management

Report this content

Tony Hoos, Head of R&D and Medical Affairs (RDMA), and Chief Medical Officer (CMO), is leaving Sobi.


Lydia Abad-Franch, MD. MBA., currently Head of Medical Affairs & Clinical Science at Sobi is appointed acting CMO effective today. She will lead the RDMA function in close collaboration with the RDMA Leadership team, supported by Board Member and former Head of RDMA & CMO Anders Ullman, MD. PhD., until a new Head of RDMA & CMO is appointed.


Lydia brings extensive experience and knowledge from the global pharmaceutical industry as well as from being a practicing Medical Doctor. Lydia is based in Basel, Switzerland, and will report to CEO Guido Oelkers and be part of the Sobi Executive Committee whilst holding this position.



Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East, Asia and Australia. In 2022, revenue amounted to SEK 18.8 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at, LinkedIn and YouTube.


For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.


Swedish Orphan Biovitrum AB (publ)
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00